Veradermics presents positive VDPHL01 data from two male pattern hair loss trials
MANE•Veradermics said VDPHL01 met both co-primary efficacy endpoints in two male studies, with Study 304 showing hair-count gains of up to 36.4 hairs/cm² at six months. Study 302 extension results are expected in the fourth quarter of 2026.
1. Trial results
Veradermics said its oral hair-loss treatment VDPHL01 met both co-primary efficacy endpoints in two registration-directed male studies, with statistically significant benefits versus placebo. In Study 304, hair-count gains reached up to 36.4 hairs/cm² at six months, and 68.7% of participants reported being improved or much improved. The studies reported no treatment-related serious adverse events or adverse events of special interest of cardiac origin.
2. Upcoming results
Topline results from the Study 302 treatment extension are expected in the fourth quarter of 2026. The female Phase 2/3 study is fully enrolled with 556 participants, with initial topline results expected in the first half of 2027.
